LARVOL is pleased to present a moderated discussion with top oncologists following AACR's Annual Meeting 2021. In the video below, Dr. Benjamin Weinberg, Dr. Kristen Ciombor, and Kinisha Gala discuss the practice-changing impact of AACR presentations in gastrointestinal cancers.
On April 19, 2021 LARVOL hosted an oncology panel discussion on the top gastrointestinal cancer clinical trial abstracts presented during the American Association for Cancer Research (AACR) Annual Meeting 2021, held on April 10-15, 2021. LARVOL's Kinisha Gala moderated the discussion between GI KOLs - Dr. Benjamin Weinberg from Gerogetown University and Dr. Kristen Ciombor from Vanderbilt University.
The discussion covered AACR abstract # CT010 Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements and AACR abstract # CT009 IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Highlights from this discussion include insight into the complicated decision-making process when faced with multiple therapeutic options for the same setting in the same patient population.
Watch this video for the full discussion:
Our AACR Panel Series covered five therapeutic areas including gastrointestinal cancer. Click below to read more about them and watch their video analysis.